Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | GMNN | O75496 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26108082 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL26304221 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL29977744 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL30578419 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL25405235 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL30578428 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL25405343 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL24715378 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL24215521 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 | |
| SCHEMBL29977561 | 1.00 | MAPK1 (0.58) | MAPK1MAPTLMNADNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285796-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. | 2024-08-29 | — | — | US | disclosed |
| EP-4326235-A2 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | Generation Bio Co. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117545469-A | Cationic lipids and compositions thereof | 世代生物公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | GENERATION BIO CO. | 2023-10-12 | — | — | US | disclosed |
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | GENERATION BIO CO. | 2023-10-12 | — | — | US | disclosed |
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | GENERATION BIO CO. | 2023-10-12 | — | — | US | disclosed |
| WO-2023177655-A1 | HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS OF USE | GENERATION BIO CO. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-116437964-A | Methods for encapsulating polynucleotides into reduced size lipid nanoparticles and novel formulations thereof | 世代生物公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4181948-A2 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | Generation Bio Co. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022226008-A2 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | POLN, POLRMT, LIPG | MAPK1 4113/4885MAPT 1642/4885LMNA 92/4885 |
| US-20240285796-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | C1R, LRBA, LIPG | MAPK1 3230/4885MAPT 3019/4885LMNA 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.